Danaher (DHR) Tops Q3 EPS by 14c; offers outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Danaher (DHR) PT Lowered to $277 at Baird
October 23, 2024 6:25 AM EDTBaird analyst Catherine Schulte lowered the price target on Danaher (NYSE: DHR) to $277.00 (from $278.00) while maintaining a Outperform rating.
The analyst comments "Maintain Outperform rating, new $277 price target (-$1). DHR reported 3Q results ahead of expectations, driven by Biotechnology and Cepheid respiratory upside.... More
Danaher (DHR) PT Lowered to $275 at Leerink Partners
October 23, 2024 6:05 AM EDTLeerink Partners analyst Puneet Souda lowered the price target on Danaher (NYSE: DHR) to $275.00 (from $280.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: We see DHR as the leader in the highly attractive, spec'd-in and recurring rev market of bioprocess tools,... More
